Deucravacitinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), CIPM (Spain) and DMC (Denmark), among others, recommended or restricted deucravacitinib, while HAS (France) did not recommend it.
Where deucravacitinib met resistance it was usually narrowed rather than refused: 3 of 8 decisive outcomes were recommendations with restrictions, against 1 outright refusal.
Every record falls within a 1.4-year window, 2022 to 13 Dec 2023 — a compressed review cycle.
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
3 distinct indication wordings are recorded for deucravacitinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 12 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess deucravacitinib, in 2022; CIPM (Spain) did not open a file until 13 Dec 2023 — a moderate spread of 1.4 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 9 of 12 dated records fall in 2023 alone.
Restriction is doing real work here: 3 of 8 decisive outcomes narrowed deucravacitinib to a subgroup rather than accepting or refusing it outright, at HIRA (South Korea), NICE (England) and SMC (Scotland).
2 of the 10 agencies here assessed deucravacitinib more than once, PBAC (Australia) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for deucravacitinib.
The full ledger for deucravacitinib reads 4 recommended, 3 restricted, 1 not recommended and 1 no benefit, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 13 Dec 2023 | LABORATORIO MEDICAMENTO FORMATO CN Precio € Criterios para la financiación ACCORD HEALTHCARE, S.L .U ORGOVYX 120 MG COMP… | financed by the SNS · art. 92 a, c | source |
| SMC (Scotland) | 11 Dec 2023 | Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. | accepted (restricted) | source |
| HIRA (South Korea) | 7 Dec 2023 | 제약 판상 건선 | reimbursable only at the evaluated price | source |
| HAS (France) | 22 Nov 2023 | Listing (Transparency Committee) | SMR insufficient · ASMR V | source |
| G-BA (Germany) | 5 Oct 2023 | Sotyktu — benefit assessment §35a | added benefit: not proven | source |
7 further decisions for deucravacitinib, across 5 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 12 decisions for deucravacitinib from 10 agencies, 2022 to 2023. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.